Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenues	$ 166,028	$ 207,709
Cost of sales	(103,372)
Gross profit	62,656	207,709
Research and development expenses (Note 14)	(1,297,274)	(1,935,085)
Selling and marketing expenses	(152,065)	(92,053)
General and administrative expenses (Note 14)	(2,703,344)	(5,080,725)
Operating loss	(4,090,027)	(6,900,154)
Financing income (expenses), net (Note 15)	(784,141)	2,746
Changes in fair value of commitment to issue shares  )Note 10)	(28,312)
Impairment of non-consolidated entity (Note 8)		(151,015)
Loss before equity in net loss of equity investments	(4,902,480)	(7,048,423)
Less: Equity in net loss of equity investments		(1,977)
Net loss	(4,902,480)	(7,050,400)
Net loss attributable to non-controlling interests	208,480	71,052
Net loss attributable to the Company’s stockholders	$ (4,694,000)	$ (6,979,348)
Basic net loss per share	$ (0.00)	$ (0.00)
Diluted net loss per share	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding used in computing basic net loss per share	540,817,628,239	520,060,275,576
Weighted average number of shares outstanding used in computing diluted net loss per share	540,817,628,239	520,060,275,576
Comprehensive loss:
Other comprehensive income (loss) - Foreign currency translation adjustments	$ 22,014	$ (28,411)
Comprehensive loss	(4,880,466)	(7,078,811)
Net - loss attributable to non-controlling interests	208,480	71,052
Other comprehensive income (loss) attributable to non-controlling interests - foreign currency translation adjustments	(10,787)	13,243
Comprehensive loss attributable to the Company’s stockholders	$ (4,682,773)	$ (6,994,516)